



Retraction

RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanterin Brain Delivery Augmentation Via the Nasal Route. *Nanomaterials* 2020, 10, 1270

Osama A. A. Ahmed ^{1,2}, Usama A. Fahmy ^{1,*}, Shaimaa M. Badr-Eldin ^{1,3}, Hibah M. Aldawsari ¹, Zuhier A. Awan ⁴, Hani Z. Asfour ⁵, Ahmed K. Kammoun ⁶, Giuseppe Caruso ⁷, Filippo Caraci ^{7,8}, Anas Alfarsi ¹, Raniyah A. Al-Ghamdi ⁹, Rawan A. Al-Ghamdi ¹⁰ and Nabil A. Alhakamy ^{1,2,11}

¹ Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; oaahmed@kau.edu.sa (O.A.A.); smbali@kau.edu.sa (S.M.B.-E.); haldosari@kau.edu.sa (H.M.A.); mr_alfarsi8@hotmail.com (A.A.); nalhakamy@kau.edu.sa (N.A.A.)

² Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

³ Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt

⁴ Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia; zawan@kau.edu.sa

⁵ Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia; hasfour@kau.edu.sa

⁶ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; akammoun@kau.edu.sa

⁷ Oasi Research Institute-IRCCS, Via Conte Ruggero, 73, 94018 Troina (EN), Italy; gcaruso@oasi.en.it (G.C.); carafil@hotmail.com (F.C.)

⁸ Department of Drug Sciences, University of Catania, 95125 Catania, Italy

⁹ Ibn Sina National College for Medical Studies, Clinical Pharmacy Department, Jeddah 22421, Saudi Arabia; ranoabg@hotmail.com

¹⁰ Ibn Sina National College for Medical Studies, Jeddah 22421, Saudi Arabia; rawanaasg3@gmail.com

¹¹ Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia

* Correspondence: uahmedkauedu.sa@kau.edu.sa; Tel.: +966-599120686



Citation: Ahmed, O.A.A.; Fahmy, U.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Awan, Z.A.; Asfour, H.Z.; Kammoun, A.K.; Caruso, G.; Caraci, F.; Alfarsi, A.; et al.

RETRACTED: Ahmed et al.
Application of Nanopharmaceutics for Flibanterin Brain Delivery Augmentation Via the Nasal Route. *Nanomaterials* 2020, 10, 1270. *Nanomaterials* 2024, 14, 174. <https://doi.org/10.3390/nano14020174>

Received: 18 December 2023

Accepted: 5 January 2024

Published: 12 January 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

The Journal retracts the article “Application of Nanopharmaceutics for Flibanterin Brain Delivery Augmentation Via the Nasal Route” [1].

Following the publication, concerns were brought to the attention of the Editorial Office regarding the overlapping figures between publications [1,2], representing different experimental conditions. More specifically, subfigures B and D of Figure 6 in publication [2] are duplicated as subfigures D and C of Figure 6 in publication [1], respectively.

The authors cooperated with the investigation and commented that the mistake occurred while finalizing the figures for both studies, and the wrong image was selected for publication [1]. The authors also provided raw data and other documents related to the histopathological experiments in the reported study. However, the Editorial Board and Editor in Chief determined that the evidence and explanation provided were insufficient to justify the overlap observed, and inconsistencies in the raw data provided meant that serious doubts remained regarding the reliability of the data provided. As a result, the Editorial Board and Editor in Chief were unable to confirm the reliability of the findings and subsequently decided to retract this paper.

This retraction was approved by the Editor in Chief of the journal *Nanomaterials*.

The authors did not agree to this retraction.

References

1. Ahmed, O.A.A.; Fahmy, U.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Awan, Z.A.; Asfour, H.Z.; Kammoun, A.K.; Caruso, G.; Caraci, F.; Alfarsi, A.; et al. RETRACTED: Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. *Nanomaterials* **2020**, *10*, 1270. [[CrossRef](#)] [[PubMed](#)]
2. Fahmy, U.A.; Ahmed, O.A.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Okbazghi, S.Z.; Awan, Z.A.; Bakhrebah, M.A.; Alomary, M.N.; Abdulaal, W.H.; Medina, C.; et al. RETRACTED ARTICLE: Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin. *Int. J. Nanomed.* **2020**, *15*, 5253–5264. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.